Benefit of analyst supportI know these comps we find are all anecdotal and we can find an equal number of smaller market cap companies further along or similar to THTX. But they are points of information for us nonetheless.
I saw an interesting oncology name today. What's interesting is that the technology sounds really risky, there's big pharma competitors and they are all in discovery mode, not trials. It's called Tango therapeutics (TNGX) and it's approach is genetic design called synthetic lethality which seems rather complicated to me.
Market Cap: $1.3bil
Cash : .4 bil
The analyst expects the peak size of the market for their lead product is $500mil in 2030 and no real reveneus until 2026. There are other indications that kick in but the only other one with decent near term revenues has peak sales of $170mil. The Barclays analyst values all this with a target implying a $1.7bil market cap.
Rather than be frustrated, shows the kind of opportunity should we see both good data and analyst coverage. Using these sort of parameters, not hard to see SORT1+ could be worth a few billion rather easily if the data they see is remotely close to what the pre-clinical showed.